Burlingame, Feb. 13, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and expected to exhibit a CAGR of 11.2% over the forecast period (2022-2030).
Key Trends and Analysis of the Global Epidermolysis Bullosa Market:
Key trends in the market include launches and approvals of novel products, and collaborations, partnerships, mergers, and acquisitions among key players. These key trends are expected to aid in the epidermolysis bullosa market growth.
For instance, in November 2021, Krystal Biotech reported that the GEM-3 clinical trial of its experimental gene therapy, beremagene geperpavec (B-VEC), for treating dystrophic epidermolysis bullosa met the primary goal.
Key players operating in the global epidermolysis bullosa market are focusing on the adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations to strengthen their presence in the global market. For instance, in November 2021, Abeona Therapeutics Inc., a gene and cell therapy company, announced its sponsorship of the second annual venture into cures, a virtual event supporting epidermolysis bullosa Research's partnership mission to find a cure for epidermolysis bullosa.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2214
Moreover, on July 11, 2017, InMed Pharmaceuticals, a preclinical stage biopharmaceutical company, entered into a research and development collaboration with ATERA SAS of France, a tissue engineering company specializing in the development of advanced human tissue models. Under the terms of the agreement, ATERA will develop 3D human skin models of epidermolysis bullosa (EB) to evaluate the in vitro drug efficacy of InMed’s lead compound, INM-750, a proprietary, topical cannabinoid product candidate targeted as a therapy in epidermolysis bullosa.
Key Market Takeaways:
The global epidermolysis bullosa market is expected to exhibit a CAGR of 11.2% over the forecast period, owing to rising product approvals. For instance, in June 2022, Amryt Pharma, a pharmaceutical company got approval from the European Commission for Filsuvez (Oleogel-S10) for the treatment of skin wounds in adults and children, ages 6 months and older, with Dystrophic Epidermolysis Bullosa (DEB) or Junctional Epidermolysis Bullosa (JEB).
Among product type, antibiotics segment is estimated to account for the largest market share in 2022.
Competitive Landscape:
Key players operating in the global epidermolysis bullosa market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegenRx, Krystal Biotech, RHEACELL Gmbh, Holostem Terapie Avanzate, StemRim/Shinogi, and Phoenix Tissue Repair.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2214
Market Segmentation:
- Global Epidermolysis Bullosa Market, By Product Type:
- Antibiotic
- Analgesics
- Others
- Global Epidermolysis Bullosa Market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Epidermolysis Bullosa Market, By Region:
- North America
- By Country
- U.S.
- Canada
- By Country
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- By Country
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- By Country/Region
- North America
Related Market Intelligence Reports:
Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Elafibranor, Ocaliva, Selonsertib, Cenicriviroc, Emricasan, and Other Therapeutics), By Diagnostics (Imaging Techniques, Diagnostic Tests, and Biopsy), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030
Migraine Therapeutic Market, By Therapeutics (Pain-relieving Medications and Preventive Medications), By Route of Administration (Oral and Nasal and Injection), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
